Stereotactic radiotherapy for large solitary brain metastases

Stereotactic radiotherapy for large solitary brain metastases
复制标题

DOI:
10.1016/j.canrad.2013.12.003
复制
发表时间:
2014-03-01
影响因子:
1.3
通讯作者:
Mazeron, J-J
Mazeron, J-J
中科院分区:
医学4区
文献类型:
--
作者:
Feuvret, L.;Vinchon, S.;Mazeron, J-J

文献摘要

被引文献

相似文献

Purpose. - To assess effectiveness and toxicity levels of stereotactic radiation therapy without whole brain radiation therapy in patients with solitary brain metastases larger than 3 cm.Patients and methods. - Between June 2007 and March 2009, 12 patients received fractionated stereotactic radiation therapy and 24 patients underwent stereotactic radiosurgery. For the fractionated stereotactic radiation therapy group, 3 x 7.7 Gy were delivered to the planning target volume (PTV); median volume and diameter were 29.4 cm(3) and 4.4 cm, respectively. For the stereotactic radiosurgery group, 14 Gy were delivered to the PTV; median volume and diameter were 15.6 cm(3) and 3.7 cm, respectively.Results. - Median follow-up was 218 days. For the fractionated stereotactic radiation therapy group, local control rates were 100% at 360 days and 64% at 720 days; for the stereotactic radiosurgery group, rates were 58% at 360 days and 48% at 720 days (P = 0.06). Median survival time was 504 days for the fractionated stereotactic radiation therapy group and 164 days for the stereotactic radiosurgery group (P = 0.049). Two cases of grade 2 toxicity were observed in the fractionated stereotactic radiation therapy group, and 6 cases of grade 1-2 toxicity, in the stereotactic radiosurgery group.Conclusions. - This study provides data to support that fractionated stereotactic radiation therapy without whole brain radiation therapy with a margin dose of 3 fractions of 7.7 Gy for treatment of solitary large brain metastases is efficient and well-tolerated. Because of the significant improvement in overall survival, this schedule should be assessed in a randomized trial. (C) 2013 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.